Evidence map›Paper›PMID 34372948›Full record

ArticleCardio-oncology (London, England)2021

Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: results from the american heart association COVID-19 cardiovascular disease registry.

David M Tehrani, Xiaoyan Wang, Asim M Rafique, Salim S Hayek, Joerg Herrmann, Tomas G Neilan, Pooja Desai, Alicia Morgans, Juan Lopez-Mattei, Rushi V Parikh and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardio-oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

David M TehraniDivision of Cardiology, Department of Medicine, University of California, Los Angeles Health System, Los Angeles, CA, USA.
Xiaoyan WangDivision of General Internal Medicine and Health Service Research, Department of Medicine, University of California, Los Angeles Health System, Los Angeles, CA, USA.
Asim M RafiqueDivision of Cardiology, Department of Medicine, University of California, Los Angeles Health System, Los Angeles, CA, USA.
Salim S HayekDivision of Cardiology, Department of Medicine, Michigan Medicine, Ann Arbor, MI, USA.
Joerg HerrmannDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Tomas G NeilanDivision of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Pooja DesaiDepartment of Medicine, University of California, Los Angeles Health System, Los Angeles, CA, USA.
Alicia MorgansDivision of Hematology and Oncology, Department of Medicine, Northwestern Memorial Hospital, Chicago, IL, USA.
Juan Lopez-MatteiDivision of Cardiology, Department of Medicine, Texas MD Anderson Cancer Center, Houston, TX, USA.
Rushi V ParikhDivision of Cardiology, Department of Medicine, University of California, Los Angeles Health System, Los Angeles, CA, USA.
Eric H YangDivision of Cardiology, Department of Medicine, University of California, Los Angeles Health System, Los Angeles, CA, USA. Ehyang@mednet.ucla.edu.
University of California, Los Angeles · USMassachusetts General Hospital · USMayo Clinic in Arizona · USMichigan Medicine · USNorthwestern Memorial Hospital · USThe University of Texas MD Anderson Cancer Center · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
NCATS NIH HHS UL1 TR001881UCLA Health System UTR001881
6 · The paper itself

Abstract

backgroundWhile pre-existing cardiovascular disease (CVD) appears to be associated with poor outcomes in patients with Coronavirus Disease 2019 (COVID-19), data on patients with CVD and concomitant cancer is limited. The purpose of this study is to evaluate the effect of underlying CVD and CVD risk factors with cancer history on in-hospital mortality in those with COVID-19.

methodsData from symptomatic adults hospitalized with COVID-19 at 86 hospitals in the US enrolled in the American Heart Association's COVID-19 CVD Registry was analyzed. The primary exposure was cancer history. The primary outcome was in-hospital death. Multivariable logistic regression models were adjusted for demographics, CVD risk factors, and CVD. Interaction between history of cancer with concomitant CVD and CVD risk factors were tested.

resultsAmong 8222 patients, 892 (10.8%) had a history of cancer and 1501 (18.3%) died. Cancer history had significant interaction with CVD risk factors of age, body mass index (BMI), and smoking history, but not underlying CVD itself. History of cancer was significantly associated with increased in-hospital death (among average age and BMI patients, adjusted odds ratio [aOR] = 3.60, 95% confidence interval [CI]: 2.07-6.24; p < 0.0001 in those with a smoking history and aOR = 1.33, 95%CI: 1.01-1.76; p = 0.04 in non-smokers). Among the cancer subgroup, prior use of chemotherapy within 2 weeks of admission was associated with in-hospital death (aOR = 1.72, 95%CI: 1.05-2.80; p = 0.03). Underlying CVD demonstrated a numerical but statistically nonsignificant trend toward increased mortality (aOR = 1.18, 95% CI: 0.99-1.41; p = 0.07).

conclusionAmong hospitalized COVID-19 patients, cancer history was a predictor of in-hospital mortality. Notably, among cancer patients, recent use of chemotherapy, but not underlying CVD itself, was associated with worse survival. These findings have important implications in cancer therapy considerations and vaccine distribution in cancer patients with and without underlying CVD and CVD risk factors.

Indexed as

CancerCardiovascular diseaseCOVID-19MalignancyMortalitySevere diseaseThromboembolic disease

Identifiers

PMID34372948
PMCPMC8352751
OpenAlexW3168335299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.